Comparative, open-label prospective study on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain on 2 mg dienogest/30 µg ethinyl estradiol continuous or 21/7 regimen oral contraceptive

Purpose To evaluate the effects of a continuous regimen combined oral contraceptive (COC) containing 2 mg dienogest and 30 µg ethinyl estradiol (DNG/EE) compared to a 21/7 regimen on the quality of life (QoL) and sexual function in women affected by endometriosis-associated pelvic pain.

Sixty-three women constituted the Study group treated with DNG/EE COC continuous regimen; 33 women were given DNG/EE COC in a 21/7 regimen. To define the endometriosis-associated pelvic pain, the Visual Analogic Scale was used. The Short Form-36, Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale (FSDS) were used to assess QoL, sexual function and sexual distress, respectively. The study included two follow-ups.

At 3 and 6 months of treatment there was an improvement in pain of the Study group (p < 0.001). The Control group underwent pain improvement at the second follow-up (p < 0.05). At the first and the second follow-ups, the Study group reported QoL improvements in all categories (p < 0.001). The Control group reported QoL improvements in all categories at the second follow-up (p < 0.05). At the first and the second follow-ups of the Study group, the FSFI total score had risen (p < 0.001), and the FSDS score had dropped (p < 0.001). An improvement of the FSFI score and a reduction of the FSDS score of the Control group was observed at the second follow-up (p < 0.001), but not at the first follow-up (p = NS).

Women on DNG/EE COC continuous regimen reported a reduction of endometriosis-associated pelvic pain and there was an improvement of their sexual activity and their QoL that was better than the DNG/EE 21/7 conventional regimen. Similar content being viewed by others

Huntington A, Gilmour JA (2005) A life shaped by pain: women and endometriosis. J Clin Nurs 14:1124–1132 Denny E (2004) Women’s experience of endometriosis. J Adv Nurs 46:641–648 Nnoaham KE, Sivananthan S, Hummelshoj L, Jenkinson C, Webster P, Kennedy SH, Zondervan KT (2009) Multi-centre studies of the global impact of endometriosis and the predictive value of associated symptoms. J Endometr 1:36–45 Sepulcri RP, do Amarai VF (2009) Depressive symptoms, anxiety, and quality of life in women with pelvic endometriosis. Eur J Obstet Gynecol Reprod Biol 142:53–56 Hummelshoj L, De Graaff A, Dunselman G, Vercellini P (2014) Let’s talk about sex and endometriosis. J Fam Plann Reprod Health Care 40:8–10 Hyun Shin JA, Howard FM (2011) Management of chronic pelvic pain. Curr Pain Headache Rep 15:377–385 Sinaii N, Plumb K, Cotton L, Lambert A, Kennedy S, Zondervan K, Stratton P (2008) Differences in characteristics of 1.000 women with endometriosis based on extent of disease. Fertil Steril 89:538–545 Rogers PA, D’Hooghe TM, Fazleabas A, Gargett CE, Giudice LC, Montgomery GW, Rombauts L, Salamonsen LA, Zondervan KT (2009) Priorities for endometriosis research: recommendations from an international consensus workshop. Reprod Sci 16:335–346 Kennedy S, Bergqvist A, Chapron C, D’Hooghe T, Dunselman G, Greb R, Hummelshoj L, Prentice A, Saridogan E, ESHRE Special Interest Group for Endometriosis and Endometrium Guideline Development (2005) ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod 20:2698–2704 Dunselman GAJ, Vermeulen N, Becker C, Calhaz-Jorge C, D’Hooghe T, De Bie B, Heikinheimo O, Horne AW, Kiesel L, Nap A, Prentice A, Saridogan E, Soriano D, Nelen W, European Society of Human Reproduction and Embryology (2014) ESHRE guideline: management of women with endometriosis. Hum Reprod 29:400–412 Vercellini P, Viganò P, Somigliana E, Fedele L (2014) Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol 10:261–275 Jeng CJ, Chuang L, Shen J (2014) A comparison of progestogens or oral contraceptives and gonadotropin-releasing hormone agonists for the treatment of endometriosis: a systematic review. Expert Opin Pharmacother 15:767–773 Leone Roberti Maggiore U, Remorgida V, Scala C, Tafi E, Venturini PL, Ferrero S (2014) Desogestrel-only contraceptive pill versus sequential contraceptive vaginal ring in the treatment of rectovaginal endometriosis infiltrating the rectum: a prospective open-label comparative study. Acta Obstet Gynecol Scand 93:239–247 Edelman A, Micks E, Gallo MF, Jensen JT, Grimes DA (2014) Continuous or extended cycle versus cyclic use of combined hormonal contraceptives for contraception. Cochrane Database Syst Rev 7:CD004695 Vercellini P, Pietropaolo G, De Giorgi O, Pasin R, Chiodini A, Crosignani PG (2005) Treatment of symptomatic rectovaginal endometriosis with an estrogen–progestogen combination versus low-dose norethindrone acetate. Fertil Steril 84:1375–1387 Vercellini P, Frontino G, De Giorgi O, Pietropaolo G, Pasin R (2003) Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen. Fertil Steril 80:560–563 Cheewadhanaraks S, Choksuchat C, Dhanaworavibul K, Liabsuetrakult T (2012) Postoperative depot medroxyprogesterone acetate versus continuous oral contraceptive pills in the treatment of endometriosis-associated pain; a randomized comparative trial. Gynecol Obstet Invest 74:151–156 Dmitrovic R, Kunselman A, Legro R (2012) Continuous compared with cyclic oral contraceptives for the treatment of primary dysmenorrhea: a randomized controlled trial. Obstet Gynecol 119:1143–1150 Coffee AL, Sulak PJ, Kuehl TJ (2007) Extended-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen. Contraception 75:444–449 Birtch RL, Olatunbosun OA, Pierson RA (2006) Ovarian follicular dynamics during conventional versus continuous oral contraceptive use. Contraception 73:235–243 Allen C, Hopewell S, Prentice A, Gregory D (2009) Nonsteroidal antiinflammatory drugs for pain in women with endometriosis. Cochrane Database Syst Rev 2:CD004753 The Practice Committee of the American Society for Reproductive Medicine (2014) Treatment of pelvic pain associated with endometriosis. Fertil Steril 101:927–935 Bizzarri N, Remorgida V, Leone Roberti Maggiore U, Scala C, Tafi E, Ghirardi V, Salvatore S, Candiani M, Venturini PL, Ferrero S (2014) Dienogest in the treatment of endometriosis. Expert Opin Pharmacother 15:1889–1902 Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH (2008) Classification and pharmacology of progestins. Maturitas 61:171–180 Klipping C, Duijkers I, Remmers A, Faustmann T, Zurth C, Klein S, Schuett B (2012) Ovulation-inhibiting effects of dienogest in a randomized, dose-controlled pharmacodynamic trial of healthy women. J Clin Pharmacol 52:1704–1713 Sitruk-Ware R, Nath A (2010) The use of newer progestins for contraception. Contraception 82:410–417 Grandi G, Xholli A, Napolitano A, Palma F, Cagnacci A (2015) Pelvic pain and quality of life of women with endometriosis during quadriphasic estradiol valerate/dienogest oral contraceptive: a patient-preference prospective 24-week pilot study. Reprod Sci 22:626–632 Gallagher EJ, Liebman M, Bijur PE (2001) Prospective validation of clinically important changes in pain severity measured on a visual analog scale. Ann Emerg Med 38:633–638 Ware JE, Kosinski M, Gandek B, Aaronson NK, Apolone G, Bech P, Brazier J, Bullinger M, Kaasa S, Leplège A, Prieto L, Sullivan M (1998) The factor structure of the SF-36 Health Survey in 10 countries: results from the International Quality of Life Assessment (IQOLA) project. J Clin Epidemiol 51:1159–1165 Basson R, Leiblum S, Brotto L, Derogatis L, Fourcroy J, Fugl-Meyer K, Graziottin A, Heiman JR, Laan E, Meston C, Schover L, van Lankveld J, Schultz WW (2004) Revised definitions of women’s sexual dysfunction. J Sex Med 1:40–48 Nappi RE, Albani F, Vaccaro P, Gardella B, Salonia A, Chiovato L, Spinillo A, Polatti F (2008) Use of the Italian translation of the Female Sexual Function Index (FSFI) in routine gynecological practice. Gynecol Endocrinol 24:214–219 Derogatis LR, Rosen R, Leiblum S, Burnett A, Heiman J (2002) The Female Sexual Distress Scale (FSDS): initial validation of a standardized scale for assessment of sexually related personal in distress women. J Sex Marital Ther 28:317–330 Bourdel N, Alves J, Pickering G, Ramilo I, Roman H, Canis M (2015) Systematic review of endometriosis pain assessment: how to choose a scale? Hum Reprod Update 21:136–152 Borghese B, Sibiude J, Santulli P, Lafay Pillet MC, Marcellin L, Brosens I, Chapron C (2015) Low birth weight is strongly associated with the risk of deep infiltrating endometriosis: results of a 743 case–control study. PLoS One 10:e0117387 Di Donato N, Montanari G, Benfenati A, Leonardi D, Bertoldo V, Monti G, Raimondo D, Seracchioli R (2014) Prevalence of adenomyosis in women undergoing surgery for endometriosis. Eur J Obstet Gynecol Reprod Biol 181:289–293 Vercellini P, Consonni D, Barbara G, Buggio L, Frattaruolo MP, Somigliana E (2014) Adenomyosis and reproductive performance after surgery for rectovaginal and colorectal endometriosis: a systematic review and meta-analysis. Reprod Biomed Online 28:704–713 Koga K, Takamura M, Fujii T, Osuga Y (2015) Prevention of the recurrence of symptom and lesions after conservative surgery for endometriosis. Fertil Steril 104:793–801 Miyashita M, Koga K, Takamura M, Izumi G, Nagai M, Harada M, Hirata T, Hirota Y, Fujii T, Osuga Y (2014) Dienogest reduces proliferation, aromatase expression and angiogenesis, and increases apoptosis in human endometriosis. Gynecol Endocrinol 30:644–648 Ferrari S, Persico P, Di Puppo F, Vigano P, Tandoi I, Garavaglia E, Giardina P, Mezzi G, Candiani M (2012) Continuous low-dose oral contraceptive in the treatment of colorectal endometriosis evaluated by rectal endoscopic ultrasonography. Acta Obstet Gynecol Scand 91:699–703 Caruso S, Iraci M, Cianci S, Casella E, Fava V, Cianci A (2015) Quality of life and sexual function of women affected by endometriosis-associated pelvic pain when treated with dienogest. J Endocrinol Invest 38:1211–1218 Nakamura M, Katsuki Y, Shibutani Y, Oikawa T (1999) Dienogest, a synthetic steroid, suppresses both embryonic and tumor-cell-induced angiogenesis. Eur J Pharmacol 386:33–40 Wiegratz I, Stahlberg S, Manthey T, Sänger N, Mittmann K, Lange E, Mellinger U, Palombo-Kinne E, Kuhl H (2011) Effect of extended-cycle regimen with an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on bleeding patterns, safety, acceptance and contraceptive efficacy. Contraception 84:133–143 Hee L, Kettner LO, Vejtorp M (2013) Continuous use of oral contraceptives: an overview of effects and side-effects. Acta Obstet Gynecol Scand 92:125–136 Reid RL, Fortier MP, Smith L, Mirkin S, Grubb GS, Constantine GD (2010) Safety and bleeding profile of continuous levonorgestrel 90 mcg/ethinyl estradiol 20 mcg based on 2 years of clinical trial data in Canada. Contraception 82:497–502 Nappi RE, Kaunitz AM, Bitzer J (2015) Extended regimen combined oral contraception: a review of evolving concepts and acceptance by women and clinicians. Eur J Contracept Reprod Health Care 17:1–9 Panicker S, Mann S, Shawe J, Stephenson J (2014) Evolution of extended use of the combined oral contraceptive pill. J Fam Plann Reprod Health Care 40:133–141 Stein SL (2013) Chronic pelvic pain. Gastroenterol Clin N Am 42:785–800 Greene R, Stratton P, Cleary SD, Ballweg ML, Sinaii N (2009) Diagnostic experience among 4,334 women reporting surgically diagnosed endometriosis. Fertil Steril 91:323–329 Laufer MR (2008) Current approaches to optimizing the treatment of endometriosis in adolescents. Gynecol Obstet Invest 66(Suppl 1):19–27 Vercellini P, Frattaruolo MP, Somigliana E, Jones GL, Consonni D, Alberico D, Fedele L (2013) Surgical versus low-dose progestin treatment for endometriosis-associated severe deep dyspareunia II: effect on sexual functioning, psychological status and health-related quality of life. Hum Reprod 28:1221–1230 McCormack PL (2010) Dienogest: a review of its use in the treatment of endometriosis. Drugs 70:2073–2088 Caruso S, Malandrino C, Cicero C, Ciancio F, Cariola M, Cianci A (2013) Quality of sexual life of women on oral contraceptive continued-regimen: pilot study. J Sex Med 10:460–466 Edelman AB, Gallo MF, Jensen JT, Nichols MD, Schulz KF, Grimes DA (2005) Continuous or extended cycle versus cyclic use of combined oral contraceptives for contraception. Cochrane Database Syst Rev 3:CD004695 Sauer U, Mann S, Brima N, Stephenson J (2013) Offering extended use of the combined contraceptive pill: a survey of specialist family planning services. Int J Womens Health 5:613–617 Acknowledgments The authors wish to thank: The Scientific Bureau of the University of Catania, Italy, for language support. Author information Authors and Affiliations Corresponding author Ethics declarations Conflict of interest The authors declare that they have no conflict of interest. Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent Informed consent was obtained from all women included in the study. Rights and permissions About this article Cite this article Caruso, S., Iraci, M., Cianci, S. et al. Comparative, open-label prospective study on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain on 2 mg dienogest/30 µg ethinyl estradiol continuous or 21/7 regimen oral contraceptive. J Endocrinol Invest 39, 923–931 (2016). https://doi.org/10.1007/s40618-016-0460-6 Received: Accepted: Published: Issue date: DOI: https://doi.org/10.1007/s40618-016-0460-6